TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05976685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage Occlusion
Description: Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.

Intervention type: DRUG
Group type: OTHER
Intervention: DOAC
Description: Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOAC
Description: Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
Study: NCT04535050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Renal Denervation: DENEX system

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal angiography
Description: Renal angiography
Study: NCT05410041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-NK-CD19 Cells
Description: CAR-NK-CD19 Cells, 1-3×10\^7 /KG, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/kg (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/kg (D-5\~D-3), determined by tumor burden at baseline.
Study: NCT06211933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU intervention
Description: HIFU intervention on non resectable pancreatic lesions at day 0 for each patient included
Study: NCT05640297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KMC with Massage therapy
Description: investigator will provide tactile and kinesthetic massage
Study: NCT05213793

Intervention type: DIAGNOSTIC_TEST
Intervention: multi-delay arterial spin labeling
Description: Multi-delay arterial spin labeling is a new method to evaluate the degree of the cerebral perfusion. It can obtain three parameters including CBF,CBV and ATT without radiation,which is similar to the traditional technology. Multi-delay ASL can provide more information of the acute stroke patients.
Study: NCT06461143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %4 articaine with 1:200 000 adrenaline
Description: For intraosseous anesthesia SleeperOne5 device is going to be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: %4 articaine with 1:200 000 adrenaline
Description: For intraosseous anesthesia SleeperOne5 device is going to be used.
Study: NCT06473025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on Relative Nutritional Status
Description: The intervention involves providing information on the height-for-age and weight-for-age percentiles of children relative to a reference group of healthy children based on WHO standards

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on Relative Nutritional Status
Description: The intervention involves providing information on the height-for-age and weight-for-age percentiles of children relative to a reference group of healthy children based on WHO standards

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information on Returns to Child Nutrition
Description: The intervention involves providing information on the effects of child undernutrition on long-term health, education, and labor market outcomes.
Study: NCT06648330

Intervention type: PROCEDURE
Intervention: Paraaortic retroperitoneal lymph node dissection
Description: The relationship between lactate level and mesenteric ischaemia in gynaecological cancer surgeries with paraaortic retroperitoneal lymph node dissection will be evaluated.
Study: NCT06648720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT de-escalation
Description: Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.
Study: NCT06598384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax combined with Azacytidine
Description: Patients were treated by venetoclax and azacytidine:~Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-7; Azacytidine 75 mg/m2 subcutaneous injection qd d1-5.
Study: NCT03289325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine hydrochloride for injection
Description: Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of \[0.1\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride for injection
Description: Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of \[0.9\*kg\] ml/h for 10 minutes, followed by continuous infusion at a rate of \[0.1\*kg\] ml/h until the end of surgery.~After surgery, the infusion rate will be decreased to \[0.025\*kg\] ml/h and continued until the end of mechanical ventilation.
Study: NCT06667895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory gated taVNS
Description: Electrical stimulation will be delivered in bursts during expiration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: random burst stimulation
Description: Electrical stimulation will be delivered in bursts at random timepoints during the breathing cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous stimulation
Description: Electrical stimulation will be delivered continuously for 30sec followed by a 30sec break.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Electrical stimulation will be identical to the taVNS, but the electrodes will be placed at a different position on the ear
Study: NCT06610045

Intervention type: OTHER
Intervention: No intervention
Description: No specific intervention is assess in this study.

Intervention type: OTHER
Intervention: No intervention
Description: No specific intervention is assess in this study.
Study: NCT06607835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful- compassion
Description: Online mindful-compassion weekly for four weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful-compassion and cannabis suppositories
Description: Cannabis suppositories and online mindful-compassion for vaginal pain
Study: NCT06604234

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021 in concentration of 1E09 CFU/capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator containing maltodextrin
Study: NCT06517901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Software fusion prostate biopsy
Description: Software fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using an image fusion platform such as UroNav or similar. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive fusion prostate biopsy
Description: Cognitive fusion biopsy: Each participant in this study arm will first undergo biopsy of the MRI-detected lesion using visual estimation and/or measurements of lesion. Three biopsy cores will be taken per lesion, with a maximum of three lesions being sampled per participant. Then systematic samples will be taken from the remainder of the prostate as per standard protocol (10-12 cores).
Study: NCT06620328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic ultrasonography-guided biliary drainage
Description: Skilled endosonographers performed EUS-BD with patients under conscious sedation by intravenous medication. All patients were given intravenous antibiotics prophylactically. A therapeutic curved linear array echoendoscope is positioned in the stomach with carbon dioxide insufflation. Standard 19G fine needles are used to puncture the dilated left intrahepatic bile duct or commo bile duct. Bile juice aspiration with 20ml syringe was performed to confirm intraductal puncture. After contrast medium injection, an insulated guidewire (0.025 inch VisiGlide2; Olympus Medical Systems, Tokyo, Japan) is advanced antegradely.~Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany) or an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan) according to randomization result. If needed, additional dilation can be attempted with dilating balloon. Finally, the dedicated plastic stent or partially cover

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic ultrasonography-guided biliary drainage
Description: Skilled endosonographers performed EUS-BD with patients under conscious sedation by intravenous medication. All patients were given intravenous antibiotics prophylactically. A therapeutic curved linear array echoendoscope is positioned in the stomach with carbon dioxide insufflation. Standard 19G fine needles are used to puncture the dilated left intrahepatic bile duct or commo bile duct. Bile juice aspiration with 20ml syringe was performed to confirm intraductal puncture. After contrast medium injection, an insulated guidewire (0.025 inch VisiGlide2; Olympus Medical Systems, Tokyo, Japan) is advanced antegradely.~Dilation of the needle tract is initially performed with a diathermic sheath (6Fr Cyst-Gastro set; Endoflex, Voerde, Germany) or an ultra-tapered mechanical dilator (7Fr ES Dilator; Zeon Medical Co., Tokyo, Japan) according to randomization result. If needed, additional dilation can be attempted with dilating balloon. Finally, the dedicated plastic stent or partially cover
Study: NCT06620549

Intervention type: DIAGNOSTIC_TEST
Intervention: gastric ultrasonograppy
Description: Patients will be scanned in both supine and right lateral decubitus position (RLD)s. If the antrum is visible, it will be judged if the antrum is empty in both positions or the antrum is empty in supine position and fluid apparent in RLD position suggesting a low fluid volume (\<1,5 ml/Kg). The third option is fluid apparent in both supine and RLD position, suggesting a higher fluid volume (\>1,5ml/Kg) and the last option is solid food in one or both positions.
Study: NCT06619054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: Oral single dose 50mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: Oral single dose 50mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: Oral single dose 50mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-001
Description: Oral single dose 50mg.
Study: NCT06618612

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PuraPly AM
Description: PuraPly Antimicrobial Wound Matrix is a 2-layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PuraPly XT
Description: PuraPly Antimicrobial XT Wound Matrix is a 5- layer cross-linked extracellular matrix (PCMP) scaffolding that consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB)
Study: NCT06619288

Intervention type: DRUG
Intervention: B/F/TAF
Description: Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.

Intervention type: DRUG
Intervention: B/F/TAF
Description: Take one tablet per dose, once daily. Each tablet contains bictegravir (BIC) 50 mg, emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 25 mg.

Intervention type: DRUG
Intervention: TDF+3TC+EFV
Description: Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).

Intervention type: DRUG
Intervention: TDF+3TC+EFV
Description: Take five tablets per dose, once daily. Each dose contains one tablet of tenofovir (TDF) 300 mg, one tablet of lamivudine (3TC) 300 mg, and three tablets of efavirenz (EFV) 200 mg (totaling 600 mg).

Intervention type: DRUG
Intervention: DTG/3TC
Description: Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.

Intervention type: DRUG
Intervention: DTG/3TC
Description: Take one tablet per dose, once daily. Each tablet contains dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg.
Study: NCT06620783

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Those in the exercise program group will access and undertake the exercise program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: yoga
Description: The yoga program group will access and perform the yoga program on a web or mobile platform for approximately 50 minutes per session, three times a week, for a total of 12 sessions over 4 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: active self-care
Description: The self-care group will access materials helpful for stress management via a web or mobile platform and engage in self-study three times a week, for a total of 12 sessions over 4 weeks.
Study: NCT04761549

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Adolescent Idiopathic Scoliosis
Description: Adolescent Idiopathic Scoliosis
Study: NCT06620848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642 monotherapy
Description: HRS-4642 will be administrated per dose level in which the patients are assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4642 and adebrelimab combination therapy
Description: HRS-4642 and adebrelimab will be administrated per dose level in which the patients are assigned.
Study: NCT06618131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise program with virtual reality applications for lower extremities
Study: NCT06620263

Intervention type: OTHER
Intervention: Pre-education period (PreEd)
Description: No intervention. ). In PreEd, the SUP use of patients in the ICU was observed observationally for three months (January 1, 2024 - April 1, 2024).

Intervention type: OTHER
Intervention: Post-education period (PostEd)
Description: In the study, the SUP education program in the ICU was implemented for ICU physicians after examining the patient data in the first three months of the study. In the 3-month PostEd after the education program (April 3, 2024 - July 3, 2024), SUP was only used in patients in the ICU, and no intervention was observed.
Study: NCT06617975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy program in rheumatology indication
Description: At least 4 balneotherapy sessions per day, 6 days a week during 3 consecutive weeks that may include: 1 whirlpool bath per day, 1 poultice application per day, 1 bath with immersion showers in a pool per day, a local jet shower every other day, a penetrating shower every other day.~Alternative treatments may replace penetrating shower or local jet shower, or other care, e.g., collective jet shower or steam bath. 10-minute air diffusion baths are taken in individual tubs at 37°C. Mud is applied 10 minutes as a poultice to both knees (minimum 2 per knee, 52°C), if necessary, to other painful osteoarthritis areas. 10-minute collective pool bathing takes place in a thermal pool equipped with jet stations immersed in water at 32°C. 3-minute local jet shower is applied to the predefined area using thermal water at 37°C. 10-minute penetrating showers are delivered by an affusion ramp on the patient lying down and directed on the area defined, using thermal water at 37°C.
Study: NCT06623760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Desk and chair adaptation interventions
Description: Adjustment of the height of tables and chairs to the height of each pupil in accordance with Functional sizes and technical requirements of chairs and tables for educational institutions (GB/T 3976--2014）, with a duration of intervention of one year。
Study: NCT06622694

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RD13-02
Description: Before cell infusion (Day 0), subjects will undergo a lymphodepleting chemotherapy based on the Fludarabine + Cyclophosphamide (FC regimen). Prior to the lymphodepleting chemotherapy, subjects must undergo an assessment, and only those meeting the criteria will be eligible for the lymphodepleting chemotherapy. The CAR T infusion should be performed at least 48 hours after the completion of the lymphodepleting chemotherapy. The infusion will be administered intravenously as a single dose. It should be completed within 30 minutes, with continuous cardiac monitoring during the infusion to observe heart rate (HR), blood pressure (BP), respiratory rate (R), and peripheral oxygen saturation (SpO2) for up to 2 hours post-infusion.
Study: NCT06623110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2 Injection
Description: Genetically modified live HSV-1 virus, 3.0 mL single-use glass vials, via intralesional (into a lesion) injection per protocol.
Study: NCT06622460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Dexterity Assessment
Description: to evaluate the reliability and sensitivity of the VET in healthy. Their performance helps define normal thresholds and behaviors in grip force modulation and manual dexterity.
Study: NCT06624124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamified Training in Diversity Considerations in the Management of Pain and Opioid Use
Description: Use of a video game-based training platform

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training in Diversity Considerations in the Management of Pain and Opioid Use
Description: Use of a traditional text-based training platform
Study: NCT06623578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic-assisted surgery
Description: robotic-assisted surgery via single-incision transaxillary approach

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open Surgery
Description: conventional open surgery
Study: NCT06621823

Intervention type: PROCEDURE
Group type: OTHER
Intervention: image-guided surgery technique
Description: The identification of an image-guided surgery technique capable of intraoperatively detecting the presence of lymph node metastases would overcome the disadvantages and complications of extensive staging lymphadenectomies.
Study: NCT06619249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation
Description: Long-distance runners will be supplemented with CoQ10 for 4 weeks in cross-over manner with 4 weeks of wash out period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Long-distance runners will be supplemented with placebo for 4 weeks in cross-over manner with 4 weeks of wash out period.
Study: NCT06620692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% GM-XANTHO [GM-XAN003]
Description: 5% GM-XANTHO \[GM-XAN003\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo
Study: NCT06618677

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LOW FODMAPs Diet
Description: patients will be randomized to low or standard FODMAP diet for 14 days; then, children from both arms started the wash-out period of two weeks and subsequently started the final 2-week period on standard or low FODMAP diet. The LFD will have a FODMAP content expressed in grams 0.15 g/kg/d FODMAPs (maximum 10 g/day) while the SFD will contain 0.7 g/kg/d FODMAPs (maximum 60 g/day).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LOW FODMAPs Diet
Description: patients will be randomized to low or standard FODMAP diet for 14 days; then, children from both arms started the wash-out period of two weeks and subsequently started the final 2-week period on standard or low FODMAP diet. The LFD will have a FODMAP content expressed in grams 0.15 g/kg/d FODMAPs (maximum 10 g/day) while the SFD will contain 0.7 g/kg/d FODMAPs (maximum 60 g/day).
Study: NCT06623851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoral scanner
Description: * The digital impressions will be made with the intraoral scanner following the procedure reported by the manufacturer.~* The intraoral scanning process is divided into the lower jaw scan, upper jaw scan, and bite scan stages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alginate impression
Description: Conventional impressions of both arches will be made according to the manufacturer's instructions, using steel impression trays and alginate
Study: NCT06622369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Game group
Description: Children in the play group will be allowed to choose a game that is compatible with virtual reality. Children in this group will be allowed to play the game they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Cartoon-video group
Description: Children in the cartoon-video group will be allowed to choose a cartoon they want compatible with virtual reality. Children in this group will be allowed to watch the cartoon they want for 10-15 minutes before the procedure. VR will be disinfected before and after each use in terms of infection risk.
Study: NCT06622681

Intervention type: OTHER
Intervention: No intervention
Description: No intervention